Seegene Unveils Molecular Diagnostic Test Automation System 'AIOS' at International Federation of Clinical Chemistry Congress

'Modular' System Instead of Integrated Type... Automation System Implementation Possible with Existing Molecular Diagnostic Devices

[Asia Economy Reporter Kim Ji-hee] Seegene announced on the 27th that it will showcase its new concept molecular diagnostic test automation system, ‘Seegene STARlet-AIOS (AIOS)’, at the world's largest international clinical chemistry conference AACC, held in Atlanta, USA, from the 26th to the 30th (local time).

AIOS is a new concept molecular diagnostic equipment solution that automates the molecular diagnostic testing process from nucleic acid extraction to PCR testing and result analysis. Unlike existing molecular diagnostic equipment, it is designed as a ‘modular’ system and implements a ‘syndromic-based’ molecular diagnostic test automation system by utilizing Seegene’s multiplex diagnostic reagent technology, which is significant.

Other global companies’ molecular diagnostic test automation systems are designed as ‘integrated’ systems where the entire process from nucleic acid extraction to PCR is conducted through a single device. In contrast, Seegene’s AIOS is a modular system that connects existing molecular diagnostic devices such as nucleic acid extraction devices and PCR devices with Seegene’s hardware and software combination method without significant changes. Therefore, hospitals and other users can implement an automation system by utilizing molecular diagnostic devices they already own, or they can acquire the entire AIOS system anew. It also offers advantages such as easy maintenance, repair, system upgrades, and the ability to use only the necessary functions like nucleic acid extraction or PCR separately.

Another feature is that it is the only system to complete a syndromic-based test automation system. Syndromic testing refers to testing multiple pathogens that cause diseases simultaneously to identify the cause at once. It is much more efficient in terms of time and cost in finding the cause of diseases. Additionally, AIOS can apply various reagents currently owned or developed by Seegene for diagnosing various respiratory diseases, HPV, and more, making it a solution to identify the causes of various symptoms experienced in daily life, according to the company.

Cheon Jong-yoon, CEO of Seegene, said, “AIOS is a syndromic-based molecular diagnostic test automation system developed by integrating the technological capabilities accumulated over the past 20 years, and it will be a new milestone that accelerates the ‘normalization of molecular diagnostics.’ Going forward, Seegene will continue to secure sustainable growth engines by expanding its portfolio of syndromic-based molecular diagnostic equipment based on its world-class diagnostic reagent technology and equipment development experience.”